AI Article Synopsis
- Epithelial ovarian cancer management has improved, but many patients still face diagnosis at advanced stages and experience relapses after initial treatment.
- Chemotherapy is the primary adjuvant treatment for early-stage tumors (FIGO stage I and II), while advanced-stage tumors (FIGO stage III/IV) typically receive carboplatin and paclitaxel-based chemotherapy, often combined with targeted therapies like bevacizumab and PARP inhibitors.
- Decisions regarding maintenance therapy depend on various factors, including FIGO stage, tumor characteristics, timing of surgery, residual tumor presence, chemotherapy response, and genetic factors such as BRCA mutations and HR status.
Article Abstract
Although the management of epithelial ovarian cancer has evolved significantly over the past few years, it remains a public health issue, as most patients are diagnosed at an advanced stage and relapse after first line treatment. Chemotherapy remains the standard adjuvant treatment for International Federation of Gynecology and Obstetrics (FIGO) stage I and II tumors, with some exceptions. For FIGO stage III/IV tumors, carboplatin- and paclitaxel-based chemotherapy are the standard of care, in combination with targeted therapies, especially bevacizumab and/or poly-(ADP-ribose) polymerase inhibitors, that have become a key milestone of first-line treatment. Our decision making for the maintenance therapy is based on the FIGO stage, tumor histology, timing of surgery (i.e. primary or interval debulking surgery), residual tumor, response to chemotherapy, BRCA mutation and homologous recombination (HR) status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2023.01.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!